Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer
The Oncologist · 2023
DOI: 10.1093/oncolo/oyad197 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2023. Verfasst von Arielle Elkrief und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NIH HHS, NCATS NIH HHS.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Direct KRASG12C inhibitors are approved for patients with non-small cell lung cancers (NSCLC) in the second-line setting. The standard-of-care for initial treatment remains immune checkpoint inhibitors, commonly in combination with platinum-doublet chemotherapy (chemo-immunotherapy). Outcomes to chemo-immunotherapy in this subgroup have not been well described. Our goal was to define the clinical outcomes to chemo-immunotherapy in patients with NSCLC with KRASG12C mutations. Patients and Methods Through next-generation sequencing, we identified patients with advanced NSCLC with KRAS mutations treated with chemo-immunotherapy at 2 institutions. The primary objective was to determine outcomes and determinants of response to first-line chemo-immunotherapy among patients with KRASG12C by evaluating objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). We assessed the impact of coalterations in STK11/KEAP1 on outcomes. As an exploratory objective, we compared the outcomes to chemo-immunotherapy in KRASG12C versus non-G12C groups.
Results
One hundred and thirty eight patients with KRASG12C treated with first-line chemo-immunotherapy were included. ORR was 41% (95% confidence interval (CI), 32-41), median PFS was 6.8 months (95%CI, 5.5-10), and median OS was 15 months (95%CI, 11-28). In a multivariable model for PFS, older age (P = .042), squamous cell histology (P = .008), poor ECOG performance status (PS) (P < .001), and comutations in KEAP1 and STK11 (KEAP1MUT/STK11MUT) (P = .015) were associated with worse PFS. In a multivariable model for OS, poor ECOG PS (P = .004) and KEAP1MUT/STK11MUT (P = .009) were associated with worse OS. Patients with KRASG12C (N = 138) experienced similar outcomes to chemo-immunotherapy compared to patients with non-KRASG12C (N = 185) for both PFS (P = .2) and OS (P = .053).
Conclusions
We define the outcomes to first-line chemo-immunotherapy in patients with KRASG12C, which provides a real-world benchmark for clinical trial design involving patients with KRASG12C mutations. Outcomes are poor in patients with specific molecular coalterations, highlighting the need to develop more effective frontline therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
ORCID-Profile: Kathryn C Arbour
Förderung
- NCI NIH HHS
- NIH HHS
- NCATS NIH HHS
- National Institutes of Health
Zitieren
APA
Elkrief, A., Riccuiti, B., Alessi, J. V., Fei, T., Kalvin, H. L., Egger, J. V., Rizvi, H., Thummalapalli, R., Lamberti, G., Plodkowski, A., Hellmann, M. D., Kris, M. G., Arcila, M. E., Baine, M. K., Rudin, C. M., Lito, P., Ladanyi, M., Schoenfeld, A. J., Riely, G. J., …, & Arbour, K. C. (2023). Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer. The Oncologist. https://doi.org/10.1093/oncolo/oyad197
Vancouver
Elkrief A, Riccuiti B, Alessi JV, Fei T, Kalvin HL, Egger JV, et al. Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer. The Oncologist. 2023. doi:10.1093/oncolo/oyad197
BibTeX
@article{Elkrief2023,
author = {Elkrief, Arielle and Riccuiti, Biagio and Alessi, Joao V and Fei, Teng and Kalvin, Hannah L and Egger, Jacklynn V and Rizvi, Hira and Thummalapalli, Rohit and Lamberti, Guiseppe and Plodkowski, Andrew and Hellmann, Matthew D and Kris, Mark G and Arcila, Maria E and Baine, Marina K and Rudin, Charles M and Lito, Piro and Ladanyi, Marc and Schoenfeld, Adam J and Riely, Gregory J and Awad, Mark M and Arbour, Kathryn C},
title = {Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer},
journal = {The Oncologist},
year = {2023},
doi = {10.1093/oncolo/oyad197}
}
EUVIMED